Compare Novo Nordisk A/S (NVO) vs Open Text Corporation (OTEX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs Open Text Corporation — how do they compare? Novo Nordisk A/S trades at $49.37 (market cap $220.53B), while Open Text Corporation trades at $22.77 (market cap $5.61B). The key difference: Novo Nordisk A/S is far larger — about 39.3× Open Text Corporation's market cap, and Open Text Corporation pays the higher dividend (4.72%). Which is the better fit depends on your goals.
| NVO | OTEX | |
|---|---|---|
Market Cap | $220.53B | $5.61B |
Sector | Health | Technology |
52-Week High | $71.70 | $39.69 |
52-Week Low | $35.29 | $20.01 |
Enterprise Value | $239.49B | $10.77B |
Dividend Yield | 3.63% | 4.72% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novo Nordisk (NVO) trades at $49.38, down 1.87% amid legal action against Eli Lilly over GLP-1 drug advertising. The stock maintains strong fundamentals with a P/E of 11.91 and robust profitability margins (net income margin 37.2%, ROE 71.4%). Recent quarterly earnings consistently beat expectations, with Q1 2026 EPS of $1.04 surpassing the $0.87 estimate. Technical indicators show a bullish moving average signal while oscillators remain neutral, with key support at $48.
Outlook remains positive given strong earnings momentum and market leadership in GLP-1 drugs, though legal risks and competitive pressures from Eli Lilly pose near-term headwinds. Analyst consensus is bullish (57.9% buy ratings) with projected revenue growth to $327.8B in 2026. Key risks include litigation outcomes and market share competition in the weight-loss drug segment.
Open Text Corporation (OTEX) trades at $23.33, up 0.26% on the day, with a bullish technical signal from moving averages and neutral oscillators. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $1.01 surpassing expectations. Fundamentals show a P/E of 11.32 and net income margin of 9.91%, while recent news highlights a $105 million investment in European AI and cloud expansion.
The outlook for OTEX is positive, supported by value-oriented valuation, consistent earnings outperformance, and strategic investments in AI. Key risks include competitive pressures in software and execution of growth initiatives. Analyst consensus suggests a 30.7% upside to the $29.75 price target, with 42% of ratings being Buy.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About Open Text Corporation
Open Text Corporation is a global leader in Enterprise Information Management (EIM) software and solutions. The company provides a comprehensive platform that helps organizations manage, secure, and leverage their unstructured digital content, including documents, emails, and media files. OTEX's offerings span content management, business process management, customer experience management, and security, serving large enterprises across various industries worldwide.
Read more on OTEX →
